Provides sales and use tax exemption for purchases of rapid or laboratory tests for purposes of detecting infections.
Summary
Assembly Bill 2983 would exempt from New Jersey sales and use tax the purchase of rapid or laboratory viral tests and antibody tests used to detect infections. The bill specifically includes, but is not limited to, molecular and antigen tests, and it references tests used to detect infections such as SARS-CoV-2. In practical terms, the measure would make these diagnostic tests tax-free at the point of sale.
The exemption would take effect immediately upon enactment, but it would apply only to sales occurring on or after the first day of the second month following enactment. The bill is framed as a supplement to the existing Sales and Use Tax Act, meaning it would carve out a new exemption within current tax law rather than create a separate program or benefit.
Impact
If enacted, the bill would amend the scope of New Jersey’s Sales and Use Tax Act by excluding receipts from sales of qualifying infection-detection tests from taxation. This would reduce the sales tax burden on consumers and purchasers of rapid tests, laboratory tests, molecular tests, antigen tests, and antibody tests used for diagnostic purposes. The practical effect would be to lower out-of-pocket costs for individuals, health providers, employers, and other entities buying these tests in New Jersey.
Sentiment
Because there are no committee transcripts or recorded votes provided, there is no documented debate or formal voting record to gauge legislative sentiment. Based on the bill’s text, the measure appears to be a straightforward tax relief proposal aimed at making diagnostic testing more affordable. The absence of recorded opposition or amendments in the provided materials suggests no identifiable controversy in the available record, though that does not indicate final legislative support or opposition.
Contention
No specific points of contention are documented in the provided materials. Potential issues that could arise in discussion include the revenue impact of exempting test sales from tax, the breadth of the exemption for different kinds of infection-related tests, and whether the tax break should be limited to particular public health emergencies or extended broadly to all qualifying tests. However, none of these concerns are attributed to any person or committee in the supplied record.